# A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

> **NCT00996567** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 22 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Cetuximab (Erbitux)

## Key facts

- **NCT ID:** NCT00996567
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996567, "A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00996567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*